Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real life study evaluating efficacy and safety of combination of Carfilzomib, Lenalidomide and Dexamethasone in patients with relapsed and refractory multiple myeloma

Trial Profile

A real life study evaluating efficacy and safety of combination of Carfilzomib, Lenalidomide and Dexamethasone in patients with relapsed and refractory multiple myeloma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2022 Results assessing the efficacy and safety of carfilzomib, in combination with lenalidomide-dexamethasone as salvage regimen in patients with refractory multiple myeloma, published in the Clinical Lymphoma, Myeloma & Leukemia.
    • 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
    • 04 Jun 2019 Results (n=41) assessing efficacy of Carfilzomib-Lenalidomide-Dexamethasone in multiple myeloma patients, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top